New weekly shot aims for major, Long-Term weight loss
NCT ID NCT06780449
Summary
This study is testing a new weekly injection called CagriSema to see if it helps people with obesity lose weight and keep it off long-term. About 400 adults will receive either the real medicine or a placebo (dummy medicine) for two years, followed by a one-year extension phase. Researchers will measure weight loss, health improvements, and safety over the full three years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APDP - Associação Protectora dos Diabéticos de Portugal
Lisbon, 1250-189, Portugal
-
Aarhus Universitetshospital, Steno Diabetes Center Aarhus
Aarhus, 8200, Denmark
-
Addenbrooke's Hospital_Cambridge
Cambridge, CB2 0QQ, United Kingdom
-
Aintree University Hospital
Liverpool, L9 7AL, United Kingdom
-
Alpha Recherche Clinique - Lebourgneuf
Québec, G2J 0C4, Canada
-
CHU Helora - Hôpital de Mons - Site Constantinople
Mons, 7000, Belgium
-
CUF Descobertas
Lisbon, 1998-018, Portugal
-
Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie
Brussels, 1200, Belgium
-
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598, United States
-
Dr. M.B. Jones Inc
Victoria, British Columbia, V8V 4A1, Canada
-
East West Medical Research Institute_Honolulu
Honolulu, Hawaii, 96814, United States
-
Gentofte Hospital - Center for Klinisk Metabolisk Forskning
Hellerup, 2900, Denmark
-
Holston Medical Group_Bristol
Bristol, Tennessee, 37620, United States
-
Hospital Cuf Descobertas S.A.
Lisbon, 1998-018, Portugal
-
Hospital Luz Arrabida, S.A.
Vila Nova de Gaia, 4400-346, Portugal
-
Hvidovre Hospital Endokrinologisk forsknings afsnit 159
Hvidovre, 2650, Denmark
-
Joint Clinical Research Facility - Swansea
Swansea, SA2 8PP, United Kingdom
-
L-MARC Research Center
Louisville, Kentucky, 40213, United States
-
Musgrove Park Hospital
Taunton, TA1 5DA, United Kingdom
-
North Texas Endocrine Center
Dallas, Texas, 75231, United States
-
Nova Scotia Health Authority
Halifax, Nova Scotia, B3H 2Y9, Canada
-
Premier Clinical Trial Research Network (PCTRN)
Hamilton, Ontario, L8L 5G4, Canada
-
Royal London Hospital - Blizard Institute
London, E1 2AJ, United Kingdom
-
Sjællands Universitetshospital, Køge - Medicinsk Afdeling
Køge, 4600, Denmark
-
Southmead Hospital
Bristol, BS10 5NB, United Kingdom
-
Spartanburg Medical Research
Spartanburg, South Carolina, 29303, United States
-
StudyMetrix Research LLC
City of Saint Peters, Missouri, 63303, United States
-
Sydvestjysk Sygehus Esbjerg - Medicinsk Endokrinologisk Ambulatorium, Forskningsenheden
Esbjerg, 6700, Denmark
-
ULS De Matosinhos E.P.E.- Hospital Pedro Hispano
Senhora Da Hora, Matosinhos, Matosinhos, 4464-513, Portugal
-
UZ Leuven - Endocrinology
Leuven, 3000, Belgium
-
UZA - UZ Antwerpen - Department of Endocrinology
Edegem, 2650, Belgium
-
Unidade Local de Saude de Sao Joao E.P.E
Porto, 4200-319, Portugal
-
University Hospital Coventry - WISDEM Centre
Coventry, CV2 2DX, United Kingdom
-
Valley Clinical Trials
Covina, California, 91723, United States
-
Washington Cntr Weight Mgmt
Arlington, Virginia, 22206, United States
-
Yale University School Of Medicine
New Haven, Connecticut, 06519, United States
Conditions
Explore the condition pages connected to this study.